A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Design Therapeutics, Inc.
DSGN
$674M
Mkt Cap
$11.78
+1.29%
Design Therapeutics, Inc. (DSGN) has a 5-year average return on invested capital (ROIC) of -26.1%. This is below average and may indicate limited pricing power.
Design Therapeutics, Inc. (DSGN) has a market capitalization of $736M. It is classified as a small-cap stock.
Design Therapeutics, Inc. (DSGN) does not currently pay a regular dividend.
Design Therapeutics, Inc. (DSGN) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Design Therapeutics, Inc. (DSGN) generated $-55 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Design Therapeutics, Inc. (DSGN) has a debt-to-equity ratio of 0.01. This indicates a conservatively financed balance sheet.
Design Therapeutics, Inc. (DSGN) reported earnings per share (EPS) of $-1.22 in its most recent fiscal year.
As used in this Annual Report on Form 10-K, unless the context indicates or otherwise requires, “Design,” “our company,” “we,” “us,” and “our” refer to Design Therapeutics, Inc., a Delaware corporation. We are a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC® molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations.
| Segment | 2020 | % of Total |
|---|---|---|
Grant | $0M | 100% |
| Metric | TTM | FY2025 | FY2024 | FY2020 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | - |
| Net Income | -70M | -70M | -50M | -8.3M |
| EPS | $-1.18 | $-1.22 | $-0.88 | $-0.52 |
| Free Cash Flow | -54M | -55M | -43M | -8.7M |
| ROIC | -27.0% | -30.7% | -24.7% | -22.8% |
| Gross Margin | - | 0.0% | 0.0% | - |
| Debt/Equity | 0.00 | 0.01 | - | -0.22 |
| Dividends/Share | $0.00 | $0.00 | $0.00 | - |
| Operating Income | -79M | -79M | -62M | -8.3M |
| Operating Margin | 0.0% | 0.0% | 0.0% | - |
| ROE | -32.0% | -30.7% | - | 110.7% |
| Shares Outstanding | 62M | 57M | 56M | 16M |
| Metric | ||||
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | N/A | 0 | 0 | 0 |
| Gross Margin | N/A | 0.0% | 0.0% | N/A |
| R&D | 6.1M | 44M | 59M | 58M |
| SG&A | 2.5M | 18M | 20M | 21M |
| EBIT | -8.3M | -62M | -79M | -79M |
| Op. Margin | N/A | 0.0% | 0.0% | 0.0% |
| Net Income | -8.3M | -50M | -70M | -70M |
| Net Margin | N/A | 0.0% | 0.0% | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||
| ROIC | -22.8% | -24.7% | -30.7% | -27.0% |
| ROE | 110.7% | N/A | -30.7% | -32.0% |
| ROA | -22.7% | -18.3% | -29.2% | -30.3% |
| Cash Flow | ||||
| Op. Cash Flow | -8.7M | -43M | -54M | -54M |
| Free Cash Flow | -8.7M | -43M | -55M | -54M |
| Owner Earnings | -9.1M | -58M | -70M | -72M |
| CapEx | 76K | 340K | 193K | 121K |
| Maint. CapEx | 5K | 1.7M | 622K | 2.9M |
| Growth CapEx | 71K | 0 | 0 | 0 |
| D&A | 5K | 1.7M | 622K | 2.9M |
| CapEx/OCF | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||
| Dividends Paid | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | 0.0% | 0.0% | 0.0% |
| Stock-Based Comp | 450K | 13M | 15M | 15M |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||
| Net Debt | N/A | -243M | -218M | -223M |
| Cash & Equiv. | 2.4M | 23M | 17M | 223M |
| Long-Term Debt | N/A | N/A | N/A | N/A |
| Debt/Equity | -0.22 | N/A | 0.01 | 0.00 |
| Interest Coverage | -277.7 | N/A | N/A | N/A |
| Equity | -11M | N/A | 213M | 218M |
| Total Assets | 37M | 252M | 226M | 230M |
| Total Liabilities | 2.5M | N/A | 14M | 12M |
| Intangibles | N/A | 0 | 0 | 0 |
| Retained Earnings | -12M | -227M | -297M | -315M |
| Working Capital | 34M | 240M | 211M | 217M |
| Current Assets | 36M | 248M | 224M | 227M |
| Current Liabilities | 2.3M | 8.5M | 13M | 10M |
| Per Share Data | ||||
| EPS | -0.52 | -0.88 | -1.22 | -1.18 |
| Owner EPS | -0.57 | -1.03 | -1.22 | -1.15 |
| Book Value | -0.71 | N/A | 3.71 | 3.49 |
| Cash Flow/Share | -0.54 | -0.76 | -0.95 | -1.07 |
| Dividends/Share | N/A | 0.00 | 0.00 | 0.00 |
| Shares Out. | 15.9M | 56.4M | 57.2M | 62.4M |
| Valuation | ||||
| P/E Ratio | N/A | N/A | N/A | -10.0 |
| P/FCF | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | N/A | 3.4 |
| Price/Sales | N/A | N/A | N/A | N/A |
| FCF Yield | N/A | N/A | N/A | -7.4% |
| Market Cap | N/A | 0 | 0 | 736M |
| Avg. Price | N/A | 0.00 | 0.00 | 11.78 |
| Year-End Price | N/A | 0.00 | 0.00 | 11.78 |
Design Therapeutics, Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
Design Therapeutics, Inc. (DSGN) has a return on equity (ROE) of -30.7%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 3 years of financial data for Design Therapeutics, Inc. (DSGN), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Design Therapeutics, Inc. (DSGN) has a book value per share of $3.71, based on its most recent annual SEC filing.
No recent press releases.